Skip to main content

Jupiter Neurosciences Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.

Current Price

$0.24

+16.93%
Profile
Valuation (TTM)
Market Cap$7.06M
P/E-0.77
EV
P/B
Shares Out29.44M
P/Sales174.48
Revenue$40448.00
EV/EBITDA

Jupiter Neurosciences Inc (JUNS) Valuation

JUNS Valuation Metrics

FCF$-5.41M
FCF Growth Rate
EPS Growth (CAGR)
WACC10.00%

JUNS Valuation & Fair Value Analysis

Jupiter Neurosciences Inc (JUNS) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.

The price-to-earnings (P/E) ratio is -0.77. Price-to-sales ratio is 174.48. PEG ratio is -0.04.

GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Jupiter Neurosciences Inc's intrinsic value.